This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Agulnik, M. Articles by Siu, L. L. Search for Related Content PubMed PubMed Citation Articles by Agulnik, M. Articles by Siu, L. L. Related Articles Related Correspondence Social Bookmarking                            What's this?

Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents

Mark Agulnik, Amit M. Oza, Gregory R. Pond, Lillian L. Siu

From the Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada

Address reprint requests to Lillian L. Siu, MD, Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Suite 5-718, Toronto, Ontario, M5G 2M9, Canada; e-mail: Lillian.siu{at}uhn.on.ca

PURPOSE: To assess the impact and perceptions of patients, physicians, and institutional review board members (IRBs) on the issue of mandatory serial tumor biopsies to acquire tissues for correlative studies.

PATIENTS AND METHODS: Complementary, self-administered questionnaires were circulated to trial patients who had previously undergone serial research-related biopsies (TPs), clinic patients who had prior diagnostic but not research-related biopsies (CPs), academic medical oncologists in Canada (MOs), and IRBs at the affiliated academic centers.

RESULTS: Ten (72%) of 14 TPs, 265 (82%) of 325 CPs, 137 (66%) of 209 MOs, and 142 (49%) of 291 IRBs responded. A 5% to 10% risk of a major biopsy complication was acceptable to 22% of CPs but only to 1% of MOs or IRBs. Anxiety was reported by 30% of TPs and 45% of CPs before their biopsies. More than 82% of MOs or IRBs believed the average patient would have at least borderline anxiety before their biopsy. Among the patients, 84% would authorize their samples for additional unrelated research and 75% would agree to genetic testing. Nearly all MOs and 86% of IRBs considered it ethical to request for additional unrelated research testing. With respect to genetic testing, 82% of MOs and 72% of IRBs would request it.

CONCLUSION: Although nearly all MOs and IRBs see the value in the biopsy, their threshold for acceptable risk is lower and they anticipate more associated anxiety than patients. Most patients recalled a tendency to tolerate their biopsies well with an average associated anxiety, and would allow their specimens to be tested for research purposes.

Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, Orlando, FL.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Performance of Biopsies in Clinical Research
  Stephen A. Cannistra
  JCO 2007 25: 1454-1455 [Full Text]

This article has been cited by other articles:

				C. Simmons, N. Miller, W. Geddie, D. Gianfelice, M. Oldfield, G. Dranitsaris, and M. J. Clemons Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann. Onc., September 1, 2009; 20(9): 1499 - 1504. [Abstract] [Full Text] [PDF]

				B. Lee, A. Lim, A. Lalvani, M. J. L. Descamps, R. Leonard, S. Nallamala, J. S. Lewis, R. C. Coombes, and J. Stebbing The clinical significance of radiologically detected silent pulmonary nodules in early breast cancer Ann. Onc., December 1, 2008; 19(12): 2001 - 2006. [Abstract] [Full Text] [PDF]

				A. P. Brown, D. S. Wendler, K. A. Camphausen, F. G. Miller, and D. Citrin Performing Nondiagnostic Research Biopsies in Irradiated Tissue: A Review of Scientific, Clinical, and Ethical Considerations J. Clin. Oncol., August 20, 2008; 26(24): 3987 - 3994. [Abstract] [Full Text] [PDF]

				A. Italiano, C. Massard, R. Bahleda, A.-L. Vataire, E. Deutsch, N. Magne, J.-P. Pignon, G. Vassal, J.-P. Armand, and J.-C. Soria Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy Ann. Onc., April 1, 2008; 19(4): 787 - 792. [Abstract] [Full Text] [PDF]

				G. R. Pond, L. L. Siu, M. Moore, A. Oza, H. W. Hirte, E. Winquist, G. Goss, G. Hudes, and C. A. Townsley Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents J. Clin. Oncol., March 10, 2008; 26(8): 1324 - 1330. [Abstract] [Full Text] [PDF]

				J. Kimmelman Ethics at Phase 0: Clarifying the Issues J. Law Med. Ethics, December 1, 2007; 35(4): 727 - 733. [PDF]

				S. A. Cannistra Performance of Biopsies in Clinical Research J. Clin. Oncol., April 10, 2007; 25(11): 1454 - 1455. [Full Text] [PDF]